SGLT2 Inhibitor (Dapagliflozin)
Treatment for Diabetes Mellitus Type 1
Typical Dosage: Dapagliflozin 5-10 mg orally once daily
Effectiveness
70%
Safety Score
60%
Clinical Trials
14
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Dapagliflozin 5-10 mg orally once daily
Time to Effect
Days-weeks for glycemic, months-years for CV/renal benefits
Treatment Duration
Lifetime (as needed)
Evidence Quality
MODERATENumber Needed to Harm (NNH)
100(Treat 100 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$6,000
Monitoring:$200
Side Effect Mgmt:$500
Total Annual:$6,700
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$120,000/QALY
QALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$9,571
SGLT2 Inhibitor (Dapagliflozin) Outcomes
for Diabetes Mellitus Type 1
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+70%
Common Side Effects
Genital Mycotic Infections
+12%
Urinary Tract Infections
+7%
Euglycemic Diabetic Ketoacidosis (DKA)
+1.5%
Dehydration
+6%
Sources:
Active Clinical Trials
7 active trials recruiting for SGLT2 Inhibitor (Dapagliflozin) in Diabetes Mellitus Type 1
Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?
NCT06922656NOT YET RECRUITINGPHASE4
60 participants
INTERVENTIONAL
Kuwait City, Kuwait +2 more
Started: Sep 15, 2025
Triple Therapy in T1DM
NCT03899402ACTIVE NOT RECRUITINGPHASE2, PHASE3
78 participants
INTERVENTIONAL
Williamsville, United States
Started: May 1, 2019
Dapagliflozin Plus Pioglitazone in T1DM
NCT03878459RECRUITINGPHASE4
120 participants
INTERVENTIONAL
San Antonio, United States +2 more
Started: Aug 8, 2019
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin
NCT07225465NOT YET RECRUITINGPHASE2
115 participants
INTERVENTIONAL
Fitzroy, Australia +3 more
Started: Feb 1, 2026
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
NCT05938712RECRUITINGPHASE2
20 participants
INTERVENTIONAL
Toronto, Canada
Started: Oct 24, 2023
SGLT2i, Pioglitazone, and Ketone Production in T1D
NCT07056699NOT YET RECRUITINGPHASE3
24 participants
INTERVENTIONAL
San Antonio, United States
Started: Jan 30, 2026
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
NCT07309094RECRUITING
250 participants
OBSERVATIONAL
Valencia, Spain
Started: Sep 15, 2023
Completed Clinical Trials
8 completed trials for SGLT2 Inhibitor (Dapagliflozin) in Diabetes Mellitus Type 1
A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes
NCT04956263COMPLETEDPHASE2
19 participants
INTERVENTIONAL
Chula Vista, United States
Started: Jun 17, 2021
Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency
NCT05541484COMPLETEDPHASE4
21 participants
INTERVENTIONAL
St Louis, United States
Started: Oct 14, 2022
Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
NCT02518945COMPLETEDPHASE3
26 participants
INTERVENTIONAL
Buffalo, United States
Started: Aug 1, 2015
Effects of Dapagliflozin on Hormonal Glucose Homeostasis in Type 1 Diabetes
NCT04035031COMPLETEDPHASE3
13 participants
INTERVENTIONAL
Bern, Switzerland
Started: Jan 9, 2020
Effect of Dapagliflozin on IAH in T1DM
NCT03556033COMPLETEDPHASE2
15 participants
INTERVENTIONAL
Nijmegen, Netherlands
Started: Nov 23, 2018
Dapagliflozin Effects on Hypoglycemia
NCT03704818COMPLETEDPHASE1
22 participants
INTERVENTIONAL
La Jolla, United States
Started: Oct 8, 2018
Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
NCT05266404COMPLETEDPHASE1
46 participants
INTERVENTIONAL
Berlin, Germany
Started: Mar 21, 2022
Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.
NCT06374043COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Almelo, Netherlands +1 more
Started: May 11, 2021